Workshop · Pharma cold chain & GDP

AI workshop for pharma cold chain and GDP.

A tailored AI workshop for pharma logistics, pharma 3PL, pharma wholesale, vaccine distribution, clinical research and pharmacy logistics, focused on where cold chain, serialisation and GDP accountability meet. No abstract AI demo, no vendor pitch: a session run by people who build healthcare and pharma software themselves and know how a temperature excursion, a batch recall and an Annex 11 audit relate to one another.

Target audiencePharma · 3PL · wholesale
RolesQP · QA · operations · IT
FormatIn-house or online
LanguageDutch or English
ModulesSeven sector blocks
CustomisationPer organisation

What is an AI workshop for pharma cold chain & GDP?

An AI workshop for pharma cold chain and GDP is a half-day or full-day session in which we take a pharma organisation through the practical, legal and operational side of AI in temperature-sensitive medicine distribution. We deliberately work with examples from your own field: excursions on a 2–8°C route over the Brenner Pass, batch recall impact across a European pharmacy network, serialisation verifiers in wholesaler software, clinical trial materials moving from depot to site, and stock forecasting for the flu and RSV peak season, rather than generic corporate use cases.

The Netherlands is a natural hub for pharma distribution: Schiphol cargo as a cold chain hub for clinical research and vaccination programmes, and major pharma 3PL players such as Movianto, DSV Pharma, Kuehne+Nagel KN PharmaChain and CEVA Healthcare serving Europe from here. Mistakes carry real weight: an excursion that runs too long means a batch hold, an incorrect serialisation update means a failed pharmacy verification, and an AI system that influences a release decision falls under Annex 11, and potentially the high-risk category of the AI Act. We design every workshop around your reality, not around the roadmap of a TMS or WMS vendor, and we are honest about where AI is not the answer.

The second distinguishing feature: we come from software development, not management consultancy. We build custom software for healthcare and pharma ourselves, understand the sensitivities of NEN 7510-compliant development, and know how a validated quality system reacts to a new AI layer. Which blocks are covered depends on the audience: QA and QP lean on governance, validation and GDP risk assessment; operations and customer service on hands-on work and exception handling; management and IT architecture on cost and TMS/WMS/EBR integration.

What we don't do: pretend that AI makes your QP release decision redundant. A Qualified Person remains personally responsible for batch release in the European supply chain. What AI can do is give that same QP a richer picture of a possible excursion, previous deviation history or a trend on a specific route, and that is exactly what we focus the session on.

Sector context
Examples from pharma logistics, pharma 3PL, wholesale, clinical research and pharmacy logistics, not generic corporate cases
GDP-aware
EU GDP 2013/C 343/01, EU FMD, Annex 11, 21 CFR Part 11 and the AI Act treated as a single governance question, not as separate formalities
Cold chain realism
IoT sensors (BLE/NB-IoT/LoRa), validated data loggers, excursion protocols: we know the practice from our own integration work
Vendor-independent
No reseller deal with a cold chain platform, validation supplier or AI vendor, just honest advice per use case

When is this workshop relevant for your organisation?

01
Obligation

AI Act literacy (Art. 4) must be demonstrable

Since February 2025, Article 4 has required all staff who work with AI systems to be sufficiently AI-literate. In pharma distribution, that goes well beyond IT and data science: QPs, QA, RPs (responsible persons for wholesale), operations, customer service and supply planning are all covered as soon as they use AI in decisions that affect batches, patients or clinical trials. A sector-specific workshop is a pragmatic way to build that literacy for an entire department at once, and to demonstrate it to the IGJ (the Dutch Health and Youth Care Inspectorate) or in a GDP audit. You can find a more general version in the broad AI company training.

02
Cold-chain pressure

Your 2–8°C or −20°C chain has too many excursions

Temperature-sensitive medicines, such as biologicals, vaccines, ophthalmic products and clinical trial materials, face an unforgiving reality: an excursion outside the validated range means at the very least a deviation, and often a batch hold. AI anomaly detection can help you spot patterns before the excursion happens, link route and environmental factors to historical excursion behaviour, and steer stock allocation towards lower-risk routes. We cover when that is justified and when a validated rule-based system remains the more sensible choice.

03
Leadership

Your board or management is asking for an AI direction

Management sees competitors and major customers (MSD, Aspen, Pfizer, Roche, Novo Nordisk) experimenting with AI in supply chain, clinical research and patient support. A management team or board session provides the framework to make strategic choices, without leadership first having to work out for themselves what a cold-chain anomaly model or a batch recall simulator actually does in practice, and what that means legally, for validation and operationally.

04
Serialisation & FMD

You are considering AI around EU FMD flows or verifier logic

The EU FMD (2011/62/EU + Delegated Regulation 2016/161) has been operational since 2019: every pack with a unique identifier is verified at pharmacy level via a national hub system (NMVS, in the Netherlands NMVO). Wholesalers and parallel traders end up with a rich stream of verification events. AI can help detect anomalies in this stream, such as suspicious verification patterns, duplicate scans and possible fraud, but the legal frameworks are strict. For the transport and logistics context, see the AI workshop for transport & logistics.

What sets our pharma workshop apart.

Difference 01

Builders with sector context

We build custom software for healthcare and pharma, understand the requirements of NEN 7510-compliant development, and know how a TMS, a WMS, validated data logger software and an EBR package fit together. The examples come from real pharma work, not from a generic corporate sample set.

Difference 02

Vendor-independent and critical

We have no partnership with a cold-chain platform, a serialisation supplier, a QMS vendor or an AI platform. We give you an honest picture of what ChatNL, Copilot, Claude or a specialist pharma AI means for your situation, including data residency, validated-environment status and whether an EU-hosted or self-hosted solution is more realistic within your Annex 11 framework.

Difference 03

Code ownership as a principle

What we advise is in line with how we work ourselves: code ownership with your organisation, no vendor lock-in, transparent data flows and repeatable validation. For regulators, the manufacturers who commission you and your own QA department, that is a far easier story than an AI black box, especially when an IGJ inspector, an MAH auditor or a clinical study sponsor asks you to explain an algorithmic decision in your GDP chain.

Seven modules for pharma practice.

These modules are the building blocks. We combine them depending on your audience, the format (half day, full day or multi-day) and the scoping conversations beforehand. There is no fixed script, but there is a solid substantive foundation.

Module 1 — AI in 2026 for pharma

The state of LLMs, RAG, agents and multi-modal models, translated to pharma logistics, wholesale and clinical research. What is hype, and what can realistically be deployed in a validated chain.

Module 2 — AI Act + GDP + Annex 11

Risk classification for anomaly-detection models, batch-recall AI, release-support systems and patient-impact forecasts. How Annex 11 (computerised systems) and 21 CFR Part 11 relate to an AI layer, and when high-risk obligations kick in.

Module 3 — Data foundation

What you need before AI can start anywhere: clean batch and serialisation data, reliable IoT feeds (BLE, NB-IoT, LoRa, traditional data loggers), structured excursion logs and the quality of TOR records (Temperature Out of Range logs).

Module 4 — Prompts for QA and customer service

Hands-on work with real pharma documents: summarising deviation reports, sharpening CAPA wording, answering customer questions about batch recalls, translation support for multinational dossiers and preparing SOP revisions.

Module 5 — Integration strategy

How to connect AI to WMS (SAP EWM, Manhattan, Körber), TMS, eQMS (Veeva, MasterControl, TrackWise), serialisation platforms (rfxcel, TraceLink, Movilitas), clinical supply systems (IRT) and validated data-logger platforms. When to opt for an API, a validated data platform or a dedicated AI development project.

Module 6 — GDPR & patient data

Clinical trial data, patient support programmes and home delivery involve patients' personal data. We cover which legal basis an AI application needs, how a DPIA in pharma differs, and how to align GDPR with GDP-RA.

Module 7 — Roadmap

To finish, we design a first roadmap together: pilots, validation approach, validated-environment strategy, governance and investments, in a logical sequence per department.

Pre-workshop scoping

A conversation with QA, operations and IT. Departments, sensitivities and validated landscape elements form the basis for the script.

Which roles in your organisation is this workshop for?

Pharma organisations vary widely: from a marketing authorisation holder (MAH) with its own EU distribution to a pharma 3PL working for multiple manufacturers, from a wholesaler with serialisation challenges to a CTSU shipping clinical trial materials from a depot. We have designed the modules so that we can shift the emphasis per role group, sometimes with one session per group, sometimes with a mixed day with sub-sessions.

Leadership

CEO, COO and management team

Strategic decision-makers who set the organisation's AI direction. Focus: market movements, competitive position, governance, AI Act classification, validation investment choices and the relationship between the AI roadmap and the MAH or sponsor portfolio.

QA / QP / RP

QA managers, Qualified Persons and Responsible Persons

Those responsible for quality, GDP-RA, batch release and the wholesale licence. Focus: how AI relates to Annex 11, 21 CFR Part 11, release authorities, deviation management and CAPA. How far AI may assist, and where the QP draws the line.

Operations

Warehouse managers and supply planners

The engine of a pharma 3PL. Focus: cold-chain monitoring, stock forecasting with serialisation and shelf life (FEFO + FIFO + batch status), capacity for seasonal peaks (flu, RSV, allergy) and bias evaluation of AI in allocation decisions.

Customer service

Customer service and complaint handling

People who deal daily with pharmacies, hospitals, clinical trial sites and patient call centres. Focus: hands-on prompting with real customer questions, exception handling during recalls, summarising temperature reports and drafting wording for deviations.

Clinical research

CTSU and IRT managers, depot coordinators

Specialists in clinical trial materials, IRT systems, site shipments and investigator brochures. Focus: AI for per-study inventory forecasting, smarter shipment batching, kit recall impact, GDP for clinical research and the overlap with sponsor protocols.

IT & data

IT managers, data engineers, CSV leads

Architecture, integration, data quality, validation. Focus: integrations between WMS, TMS, eQMS, serialisation platforms, BI and the AI layer; when a dedicated AI development project is wiser than an ad hoc integration; how to validate an AI component within Annex 11 boundaries.

Sector use cases we cover.

During the workshop we work with use cases that pharma organisations will recognise: concrete situations on which to run the legal, technical, validation and operational analysis. Participants discover for themselves where the line falls between a useful assistant and a high-risk system that could influence a batch block or patient exposure.

A first classic is cold chain anomaly detection. A pharma 3PL continuously receives IoT feeds from reefer containers, lorries, depot locations and distribution fridges. An AI model can spot patterns that precede an excursion (a combination of outside temperature, vehicle load, route segment, door openings and gateway latency) which individual threshold rules do not catch. The value does not lie in a replacement alarm system; that remains the validated data logger. The value lies in a second signal layer that lets your QA and operations teams act earlier, and in a retrospective tool that speeds up root cause analysis after an excursion. For the broader supply chain context, see our sister page on transport.

A second is route planning for EU pharma corridors. The major flows (Schiphol to Frankfurt, Rotterdam to Basel, Eindhoven to Mainz, Belgian border corridors) have fixed bottlenecks: border handling with third countries since Brexit, terminal turnaround times, weather-sensitive mountain passes and customs handovers. AI models that combine historical ETAs, weather data and previous excursion logs can suggest routes with a statistically lower temperature risk, as a supporting signal alongside QA's validated shipping lane choice.

A third is batch recall impact analysis. In a recall, the question is where a particular batch ended up and how quickly it was distributed. AI can help quickly aggregate serialisation events (verifier scans, release events, return flows) into an operational picture: which pharmacies, which wholesale depots and which patient populations are affected. We cover which architecture makes that analysis possible and which privacy limits apply.

A fourth is inventory forecasting with serialisation and shelf life. Unlike in non-pharma, this is not just about FIFO but about FEFO (First Expired, First Out), combined with batch status (released, blocked, quarantined), MAH instructions and, for clinical research, sponsor protocols. AI forecasts must handle these additional dimensions, otherwise they steer towards a reality that does not exist.

A fifth is disruption forecasting for port and border issues. Strikes, terminal outages, sanctions changes and extreme weather disrupt pharma flows especially hard, because rerouting without a validated route is not an option. AI can combine signals from news, terminal publications, AIS data and historical disruptions into an early warning, provided the signal is not mistaken for an operational instruction.

A sixth is audit trail completion and deviation assistance. An Annex 11 or GDP audit requires traceability of changes, deviations and CAPA steps, often scattered across the eQMS, email and spreadsheets. AI can help compile draft narratives that QA then reviews and validates. We cover where that is a responsible form of support and where it becomes dangerous, namely where AI could paper over a gap in the audit trail.

These cases serve as analysis material. We work through each one in terms of AI Act classification, GDP and Annex 11 position, data quality and practical feasibility within your stack. By the end, your team has a shared view of what is sensible to investigate first — and what is not (yet).

How we approach compliance and sector reality.

Pillar 01

AI Act classification first

For every use case we discuss, we start with its classification under the AI Act. Systems that influence batch release decisions, clinical distribution decisions or patient exposure are far more likely to fall into the high-risk category than an AI that merely summarises customer emails or prepares deviation drafts.

Pillar 02

GDP + Annex 11 + 21 CFR Part 11

GDP-EU 2013/C 343/01, Annex 11 for computerised systems and, for US-bound products or MAHs, 21 CFR Part 11 together form the validated framework. We treat them as a single governance question: data flows, authorisations, retention, validation status, audit trail completeness and the relationship with the quality system.

Pillar 03

Validation reality for AI

An AI component is not classic deterministic software. What does that mean for URS, FS, DS, IQ/OQ/PQ, periodic review and change control? We walk through pragmatic answers — risk-based validation in the spirit of GAMP 5 second edition — and the documentation you need to convince an inspector or auditor that your AI layer is under control.

Sector-specific legal frameworks we work with.

There is no separate "AI law" for pharma distribution, but applying general and sector-specific regulation to AI is no formality. With any serious use case, several frameworks come into play at once.

The AI Act classifies AI systems by risk level. Crucial for pharma: Article 4 (AI literacy for everyone who works with AI — not just IT); high-risk classification for systems that influence batch release, clinical trial allocation or patient impact assessments; and the overlap with MDR/IVDR for medical devices and in vitro diagnostics. GDP-EU 2013/C 343/01 is the primary framework for Good Distribution Practice — RP responsibility, quality system, validated temperature logging, deviation management, traceability. Annex 11 (EudraLex Volume 4) governs computerised systems: validation, audit trail, electronic signatures and data integrity (ALCOA+). For US MAH flows, 21 CFR Part 11 also applies.

The EU FMD (Directive 2011/62/EU + Delegated Regulation 2016/161) requires serialisation and verification on the pharmacy side via a national hub system; wholesale and parallel import carry specific verification obligations. AI models working on those flows must handle purpose limitation, retention and NMVS/EU Hub interaction correctly. The GDPR also applies as soon as patient or clinical trial participant data comes into play, often through patient support, home delivery or post-marketing surveillance. In practice, a DPIA for pharma AI is often a combined GDP risk assessment / DPIA.

For clinical research, EU CTR 536/2014 and ICH GCP E6(R3) apply; for medical devices, MDR 2017/745 and IVDR 2017/746. For cybersecurity in healthcare IT chains, this ties in with our work on NEN 7510-compliant software. For structural AI implementation, it ties in with our AI development practice.

Format options for your organisation.

Format 01

In-house at your office or depot

We come to your office or pharma depot — Schiphol cargo zone, Eindhoven, Venlo, Maasvlakte or a specific clinical depot — with a team of two. A room with a projector and a laptop per participant is enough. For access to a validated zone, we work on visitor laptops outside the validated network.

Format 02

Online with recording

Live video call for distributed teams, also handy for international organisations with subsidiaries in Belgium, Germany, Switzerland, Ireland or the UK. Hands-on blocks run in your own browser; a recording is available for absent colleagues, provided no GxP-sensitive documents appear on screen.

Format 03

Series of half days

For larger pharma organisations this is sometimes better than one long day: a series of half days in which we serve the target groups separately — management and QA in the first session, operations and customer service in a second, clinical research and IT in a third — so that each group works with its own material.

How an engagement works in practice.

It starts with an intake — usually with the QA lead, an operations or supply representative, an IT or CSV representative and, depending on your organisation, an RP, QP or CTSU manager. We discuss the target group, existing AI activities, validated landscape, IoT suppliers, serialisation platform and eQMS stack. Based on that, we propose a programme — sent to you in advance.

The workshop then takes place. We work in clear blocks: a short introduction to the content, a longer hands-on or analysis exercise, and at the end a start on a follow-up roadmap. For hands-on blocks we ask in advance which documents you would like to use — anonymised deviation reports, fictional CAPA wording, examples of temperature reports, customer emails from complaint handling — and build the exercises around them. Afterwards you receive a written wrap-up: which modules were delivered, who attended, which priorities came up and which next steps we agreed. This material can be used as documentation for Article 4 of the AI Act and as an appendix to a GDP audit trail around AI adoption.

The workshop is not an end goal but an entry point. For some pharma organisations one session is enough — a shared picture and a set of follow-up questions for the management team. For others it becomes the trigger to carry on: a pilot on anomaly detection in the cold chain, a batch recall impact tool, or building new healthcare or pharma software in which an AI component is delivered within Annex 11 and NEN 7510 boundaries from day one. Both outcomes are legitimate.

Frequently asked questions.

Does the AI Act also apply to pharma distribution and wholesale?
Yes. Article 4 requires demonstrable AI literacy for all staff who work with AI — so also QA, QP, RP, operations, customer service and supply planning, not just IT. High-risk classification can arise as soon as an AI system has a direct effect on batch release, clinical trial allocation or patient impact assessments. Transparency requirements and documentation obligations then apply, on top of the regular GDP and Annex 11 framework.
How does AI relate to Annex 11 and validation?
Annex 11 governs computerised systems for regulated activities — risk-based, with validation, audit trail, electronic signatures and data integrity (ALCOA+). An AI component is not classic deterministic software: the same model can give different output for the same input, and retraining changes its behaviour. That calls for an adapted approach — a sharp definition of intended use, periodic review, change control around model versions, drift monitoring and clear boundaries. GAMP 5 second edition and additional AI/ML guidance are useful starting points.
Can AI make a batch release decision?
No. In the European supply chain, batch release remains the personal responsibility of a Qualified Person — a human being, registered under an MAH or manufacturer. What AI can do is give the QP a richer picture of a possible excursion, previous deviation history or a trend on a specific route. We cover which support architecture is responsible and how you ensure traceability across both the AI input and the QP's deliberation.
What is the difference with a general corporate AI training?
Our broad AI corporate training is sector-agnostic. The pharma cold-chain & GDP workshop on this page is a specific variant with sector context: GDP, Annex 11, EU-FMD, 21 CFR Part 11, cold-chain practice, serialisation, clinical trial materials and QP/RP responsibility are not standalone modules but the common thread throughout. For transport and construction logistics without a pharma component, see the AI workshop for transport & logistics.
Do you also cover clinical research and IRT systems?
Yes, in a separate block when your audience needs it. Clinical trial distribution has its own particular concerns: kit blinding, randomisation independence, country-specific regulatory requirements, sponsor protocols, depot-to-site flows and the overlap between GDP and GCP. We cover where AI can responsibly help — stock forecasting per study and site, smarter shipment batching, kit recall impact, complaint classification — and where IRT systems, sponsor instructions and EU CTR 536/2014 draw a hard line.
What do you cover on EU-FMD and serialisation?
A dedicated module for wholesalers and parallel traders. EU-FMD has been operational since 2019: every pack with a unique identifier is verified at pharmacy level via a national hub system (in the Netherlands, NMVO/NMVS). Wholesalers have specific verification obligations around risk categories and parallel import. AI can support anomaly detection on verification events, fraud signals and data completeness — provided purpose limitation, retention and EU hub interaction are tightly controlled.
How many participants, and what prior knowledge is needed?
Hands-on modules work best with groups of roughly six to twelve participants. Management and QA/QP sessions work better in a smaller setting; for larger organisations we split the group. No technical background is required: we start every module with a short levelling-up. For hands-on blocks, a working laptop is useful, plus access to an AI tool provided by your organisation (ChatNL, Copilot, Claude or a comparable business solution).
Does this workshop cover the AI Act literacy obligation?
Yes, for the participants. Modules 1, 2, 6 and 7 together amply cover what Article 4 minimally requires for pharma staff — including overlap with Annex 11 and GDP knowledge. You receive a written record, usable as documentation for the IGJ (the Dutch Health and Youth Care Inspectorate), a GDP audit or a sponsor audit. For refreshers, we recommend a recurring programme.
What happens after the workshop?
You receive a written wrap-up with priorities, agreements and recommended next steps. Optionally, we schedule a follow-up sparring session. For organisations that want to continue, we link up with our AI development practice and with the development of healthcare and pharma software within NEN 7510-compliant frameworks. The workshop carries no obligation.

Talk to us about an AI workshop for your pharma organisation.

A half-hour introductory call in which we go through which departments will take part, what your validated landscape and cold-chain stack look like, and where the first need lies. We then send a concrete proposal with modules, format and schedule.

Reply within one working day
No-obligation conversation
Westerdoksdijk 599, Amsterdam
FvD
Fabian van Dijk
Business developer · Appfront
Share LinkedIn Email

Edit content